IXHL Incannex Healthcare Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Jun 9, 2026 Processed 11d 20h ago SEC 0001213900-26-066526
8-K context-dependent: Items 7.01
Latest settled — T+5d ⚠ clustered
IXHL ▲ 0.00% at T+5d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -2.41% · entry $3.67 → $3.67
Next anchor: T+20d in 17d
Last close $3.56 (close Jun 18) · -3.00% from $3.67 entry
Entry anchored
Jun 9, 07:01 AM ET
via Databento tick
T+1d
+6.54%
call +6.54% · α +8.12%
$3.91
settled 11d ago
T+5d
0.00%
call 0.00% · α -2.41%
$3.67
settled 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Incannex Healthcare announced that Alliance Global Partners (AGP) has initiated equity research coverage with a BUY rating and an $18.00 price target. The coverage highlights the company's lead programs IHL-42X (obstructive sleep apnoea) and PSX-001 (generalized anxiety disorder). This is a routine disclosure with no new financial data or operational catalysts.

Actionable Insight

Monitor for clinical trial readouts from the DReAMzz dose optimisation study for IHL-42X and any regulatory updates for PSX-001, which would provide more material catalysts than this research coverage initiation.

Key Facts

  • Alliance Global Partners initiated equity research coverage on Incannex Healthcare with a BUY rating
  • Price target set at $18.00 per share by analyst James Molloy
  • Report dated June 8, 2026, covers IHL-42X and PSX-001 programs
  • AGP has received compensation from Incannex for providing investment banking services

Financial Impact

No financial figures reported; analyst price target of $18.00 per share vs. current market cap of $41M

Risk Factors

  • Analyst coverage does not guarantee increased investor awareness or liquidity
  • AGP has received investment banking compensation from Incannex, creating potential conflict of interest
  • Clinical-stage biotech with no approved products carries inherent development and regulatory risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-066526
Document: ea029393401ex99-1.htm0001213900-26-066526
Document: 0001213900-26-066526-index-headers.html0001213900-26-066526
Document: 0001213900-26-066526-index.html0001213900-26-066526
Document: 0001213900-26-066526.txt0001213900-26-066526
13 reports for IXHL
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+1▲ +5.52%Mar 12, 2026
Filters
Rows
Reports for IXHL — sortable, filterable
Type Now
Jun 10, 2026
10d ago
Press Release
MIXED ★ 6/10
$3.91 $3.73▼ −4.60%▼ −8.04%$3.56 (−8.95%)
Jun 10, 2026
10d ago
8-K
BULLISH ★ 5/10
$3.91 $3.73▼ −4.60%▼ −8.04%$3.56 (−8.95%)
Jun 9, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$3.67 $3.67· 0.00%▼ −2.41%$3.56 (−3.00%)
May 14, 2026
5w ago
Press Release
BULLISH ★ 6/10
$3.88 $3.64▼ −6.19%▼ −5.47%$3.56 (−8.25%)
May 14, 2026
5w ago
8-K
BULLISH ★ 5/10
$3.88 $3.64▼ −6.19%▼ −5.47%$3.56 (−8.25%)
May 12, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$3.90 $3.79▼ −2.82%▼ −2.90%$3.56 (−8.72%)
Apr 22, 2026
8w ago
8-K
BULLISH ★ 6/10
$4.09 $3.95▼ −3.42%▼ −3.48%$3.56 (−12.96%)
Mar 27, 2026
12w ago
Press Release
NEUTRAL ★ 4/10
$3.24 $2.56▼ −20.99%▼ −24.85%$3.56 (+9.88%)
Mar 25, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$3.22 $2.96▼ −8.07%▼ −7.83%$3.56 (+10.56%)
Mar 18, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$3.09 $3.22▲ +4.21%▲ +4.92%$3.56 (+15.21%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (29h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access